(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

Icotrokinra demonstrated a favorable safety profile. At Week 16, 50% of adolescents treated with icotrokinra experienced ≥1 adverse event (AE), compared to 73% of adolescents receiving placebo ...

Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 3 results for icotrokinra, a new investigational treatment ...

(RTTNews) - Drug major Johnson & Johnson (JNJ) on Tursday announced positive Icotrokinra results, which showed that 75% of adolescents with plaque psoriasis or PsO achieved completely clear skin ...

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call ...

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...